La période de renouvellement de l’accès aux normes d’HL7 International pour 2021-2022 est commencée. Veuillez renouveler votre accès d’ici le 9 avril 2021. En savoir plus >

Partager :

Le contenu créé par les communautés et les groupes de travail est accessible dans la version originale seulement.

Public Health Surveillance
Building knowledge and collaborating on public health solutions to improve the electronic sharing and use of immunization and communicable disease information.
Membres: 183
Personne-ressource: Linda Parisien
Type: Ouvert
Accès: Public
Building knowledge and collaborating on public health solutions to improve the electronic sharing and use of immunization and communicable disease information.

Activité

Taylor Rubens-Augustson a lancé une nouvelle discussion dans le groupe Public Health Surveillance
Hi everyone, A generic SNOMED-CT concept has been created for the COVID-19 non-replicating vector vaccine group (the parent concept in which the AstraZeneca, COVISHIELD and Janssen vaccines fall under): - ConceptID: 29061000087103 - FSN: Vaccine product containing only non-replicating viral vector encoding protein of Severe acute respiratory syndrome coronavirus 2 (medicinal product) - PT: COVID-19 non-replicating vector vaccine - Syn: Vaccine product containing only non-replicating viral vector encoding protein of Severe acute respiratory syndrome coronavirus 2 | COVID-19 non-replicant vector vaccine The concept is in scope for the next CVC release. It has been created in the CA Edition and is in scope for the March CA Edition publication. It will also be sent to SI for candidate in the July 2021 INT release. The full RFC can be viewed here: https://informs.infoway-inforoute.ca/browse/SCT-11026?filter=-2 (note that you must register for an InfoCentral account and request access to Informs). Please don't hesitate to let me know if you have any questions. All the best, Taylor
Taylor Rubens-Augustson a lancé une nouvelle discussion dans le groupe Public Health Surveillance
Hi everyone, Thank you for participating in the CVC Monthly Meeting last week. Please find below a summary of updates and action items. COVID-19 Terminology SNOMED-CT Codes for COVISHIELD and Janssen COVID-19 vaccine products have been created: COVISHIELD - ConceptID: 28961000087105 - FSN: COVISHIELD 0.5 milliliter solution for injection Verity Pharmaceuticals Inc. (real clinical drug) - PT: COVID-19 COVISHIELD COVID-19 VP Syn: COVISHIELD 0.5 milliliter solution for injection Verity Pharmaceuticals Inc. Janssen (Johnson & Johnson) - ConceptID: 28951000087107 - FSN: JANSSEN COVID-19 0.5 milliliter suspension for injection Janssen Inc. (real clinical drug) - PT: COVID-19 JANSSEN COVID-19 Jan Syn: JANSSEN COVID-19 0.5 milliliter suspension for injection Janssen Inc. These concepts are in scope for the next CVC release and for the March CA Edition publication. Generic agent code: COVID-19 non-replicating viral vector - An RFC has been submitted to Canada Health Infoway to create a generic agent code for COVID-19 non-replicating viral vector vaccines (in which the AstraZeneca, COVISHIELD and Janssen products would fall under). - Link to RFC: https://informs.infoway-inforoute.ca/browse/SCT-11026?filter=-2 - Timeline: a code will be ready before the end of this week. Once it has been created, the CVC team will share with working group members via email and post in the Public Health Surveillance community forum. COVID-19 Pfizer Concept Modifications - Based on published product monograph and discussions with stakeholders, modifications to the COVID-19 Pfizer vaccine concept are as follows: - FSN: PFIZER-BIONTECH COVID-19 messenger ribonucleic acid 30 micrograms per 0.3 milliliter suspension for injection BioNTech Manufacturing GmbH - PT: COVID-19 PFIZER-BIONTECH COVID-19 mRNA PB - There were no issues raised by working group members with this change Governance Update - CVC team will share a draft Terms of Reference for the CVC Working Group and for a Clinical Advisory group within two weeks to solicit feedback prior to the next monthly meeting. Next CVC Release - CVC Version 1.1.8 is scheduled to be released on March 5th. Next CVC Meeting - The next CVC Working Group Monthly Meeting will take place on Tuesday, March 30th from 2-3pm EST. Please note that you must register in advance for this meeting (see details below). When: Mar 30, 2021 02:00 PM Eastern Time (US and Canada) Register in advance for this meeting: https://infoway-inforoute.zoom.us/meeting/register/tJUud-GqrzkiGtXX4o8L9CrP4bXRKwZO0JIe Please let us know if you have any questions, comments or feedback on the above. Best, Taylor
Taylor Rubens-Augustson a lancé une nouvelle discussion dans le groupe Public Health Surveillance
Hi everyone, The meeting agenda for this afternoon's CVC Monthly Meeting has been posted in the Public Health Surveillance community under Documents > Meeting Information > 2021. If you have not already registered and wish to attend the CVC Monthly meeting, please find registration information below. When: Feb 25, 2021 02:00 PM Eastern Time (US and Canada) Register in advance for this meeting: https://infoway-inforoute.zoom.us/meeting/register/tJIuc-Cgqz8tG9J6m9tuM6zKoN5KipKKKpkK
Taylor Rubens-Augustson a lancé une nouvelle discussion dans le groupe Public Health Surveillance
Hi everyone, A SNOMED CT code for the AstraZeneca vaccine has been created: ConceptID: 28761000087108 FSN: ASTRAZENECA COVID-19 0.5 milliliter solution for injection AstraZeneca Canada Inc. (real clinical drug) PT: COVID-19 ASTRAZENECA COVID-19 AZC Syn: ASTRAZENECA COVID-19 0.5 milliliter solution for injection AstraZeneca Canada Inc. This concept is in scope for the next CVC release, and in scope for the SNOMED March CA Edition publication. Update on Generic Concept for AstraZeneca and Janssen Vaccines To expedite the process of creating a code, the AstraZeneca COVID-19 concept has been created under the most generic COVID-19 term (28531000087107 |Vaccine product against disease caused by Severe acute respiratory syndrome coronavirus 2 (medicinal product)|). However, a more granular generic term for both the AstraZeneca and Janssen vaccines is recommended when it becomes available. Based on discussions with clinical subject matter experts (Dr. Sarah Wilson, Public Health Ontario & NACI Member; Dr. Monika Naus, Medical Director, Communicable Diseases & Immunization Service & Medical Head, Immunization Programs & Vaccine Preventable Diseases at the BCCDC) and sources gathered, the AZ and Janssen vaccines are considered "viral vector" vaccines, specifically, "non-replicating viral vector" vaccines. Both use adenoviruses as the viral vector, however, they do not use the same adenovirus vector. There has not been a perceived use case for creating such granular generic concepts at the level of the specific adenovirus. Therefore, we are proposing that the AZ and Janssen vaccines fall under a parent concept, "COVID-19 non-replicating viral vector" vaccine. For a schematic overview and scholarly references for this recommendation, please refer to the PHS Community documents section, under Meeting Information > 2021 > "CVC Working Group - Update on Generic Concept for AstraZeneca and Janssen COVID-19 Vaccines" We have confirmed with Linda Parisien that a generic concept for this does not exist, and have been informed that the SNOMED International community is currently working on developing terminology for this group of vaccines. New concepts for COVID-19 vaccines are anticipated to be available within the coming weeks from SNOMED International. This is also where the COVID-19 mRNA generic concept was drawn from in December. Once an appropriate term becomes available, the CVC will adopt this term as the parent of the AZ and Janssen vaccines, assuming that the concept aligns with the recommendations we have gathered from subject matter experts. Next CVC Release To include the AstraZeneca trade name code, we are proposing to push the next CVC release to next week with the following schedule: - Tuesday, February 16th: Prerelease sent to stakeholders for review - Thursday, February 18th: Deadline to provide feedback - Friday, February 19th: CVC Release Please let me know if you have any questions or concerns with the above.

Événements



Événements à venir :
Aucun événement

Forum

Generic concept created: COVID-19 non-replicating vector vaccine 03/04/21
Hi everyone, A generic SNOMED-CT concept has been created for the COVID-19 non-replicating vector vaccine group (the parent concept in which the AstraZeneca, COVISHIELD and Janssen vaccines fall under): - ConceptID: 29061000087103 - FSN: Vacci...
CVC Working Group Meeting Summary: COVISHIELD & Janssen COVID-19 vaccine concepts created and other updates 03/02/21
Hi everyone, Thank you for participating in the CVC Monthly Meeting last week. Please find below a summary of updates and action items. COVID-19 Terminology SNOMED-CT Codes for COVISHIELD and Janssen COVID-19 vaccine products have been created...
CVC Working Group Monthly Meeting - Agenda Posted 02/25/21
Hi everyone, The meeting agenda for this afternoon's CVC Monthly Meeting has been posted in the Public Health Surveillance community under Documents > Meeting Information > 2021. If you have not already registered and wish to attend the CVC Mon...
CVC Working Group: AstraZeneca COVID-19 vaccine trade name code available & other updates 02/12/21
Hi everyone, A SNOMED CT code for the AstraZeneca vaccine has been created: ConceptID: 28761000087108 FSN: ASTRAZENECA COVID-19 0.5 milliliter solution for injection AstraZeneca Canada Inc. (real clinical drug) PT: COVID-19 ASTRAZENECA COVID-...
CVC Monthly Meeting Summary 02/04/21
Hi everyone, Thank you for your participation in last week's CVC meeting. Please find below a summary of the meeting and action items. The next CVC working group meeting is scheduled to take place on Thursday, February 25th from 2-3pm EST. Plea...
CVC Monthly Meeting 01/21/21
Hi everyone, Please join us for the next CVC monthly meeting, scheduled on Thursday, January 28 from 2-3pm EST. If you would like to attend, please note that you will need to register in advance (see Zoom registration information below). After...
COVID-19 Antigen to Agent Mapping Question 12/17/20
Hi Marc, I can comment on what we have heard from Ontario. Antigen of Severe acute respiratory syndrome coronavirus 2 (generic COVID-19 "antigen") will be sufficient for all vaccines, and is technically accurate for the mRNA vaccines. Thanks,...
COVID-19 Antigen to Agent Mapping Question 12/17/20
Hi all, We in Manitoba are wondering if other jurisdictions are planning on having a unique antigen code in Panorama for each vaccine type, e.g. mRNA, vector, and sub-unit protein? Or are you planning to associate all vaccine agents to the generic...
Canadian Vaccine Catalogue: New Version Available, including COVID-19 Terminology! 12/14/20
Hi everyone, We're pleased to announce the release of the latest version of the CVC (Version 1.1.6), which includes COVID-19 vaccine terminology. To download the latest version, visit .... To be notified of future CVC releases, .... Thank you a...
New SNOMED CT COVID-19 Tradename codes now available ! 12/11/20
Please find below the new SNOMED CT COVID-19 codes. They are in scope for the March 2021 CA Edition, and can be pre-adopted as needed. Don’t hesitate to share this notification with anyone that is not a member of this Forum. NOTE that the descrip...
Next CVC Working Group Meeting - COVID-19 Vaccine Terminology 12/04/20
Hi everyone, Please join us on Wednesday, December 9th from 12:00-1:00pm EST to continue the discussion on COVID-19 vaccine terminology. See meeting details below. You are invited to a Zoom meeting. When: Dec 9, 2020 12:00 PM Eastern Time (US...
Summary of CVC Working Group Meeting - COVID Terminology 12/04/20
Thank you to everyone who participated in the CVC Working Group Meeting yesterday on developing COVID-19 vaccine terminology. Please find below a summary of action items and next steps. COVID-19 Trade Name Concepts - Linda Parisien (Canada Health...
CVC Working Group Meeting - COVID Terminology 12/02/20
Hi everyone, Please join us tomorrow, December 3rd from 1:30-2:30pm EST for a CVC Working Group discussion on creating COVID-19 vaccine terminology. If you are interested in participating, please send an email to Taylor Rubens-Augustson at taylor@...
Cross-post: COVID-19 and Social Determinants of Health (SDOH) 11/12/20
SNOMED International is a working member of the COVID-19 Interoperability Alliance, which is currently exploring the development of value sets for Social Determinants of Health (SDOH) in the context of COVID-19. For anyone who has information on the...
SNOMED CT Drug Extension User Support Group (Cross-posting) 10/19/20
SNOMED International is establishing a Drug Extensions User Support Group, to provide support to implementers of SNOMED CT drug extensions. The group is open to any stakeholder from the SNOMED CT community who is actively using, planning to use, or i...

Documents

Cliquez sur « Gérer des documents » pour :

  • voir la liste complète des documents ou les dossiers regroupant les documents
  • téléverser un nouveau document

N. B. : Les membres des groupes ne sont actuellement pas avisés de l'ajout d'un nouveau document. Pour aviser d'autres membres, vous devez en afficher l'adresse électronique dans le forum. (La fonction d'avis de téléversement des nouveaux documents est en préparation.)

Gérer des documents Vous devez peut-être ouvrir une session et/ou être déjà membre du groupe pour accéder à ce contenu.

Vidéo

Ce groupe n'a pas de video.

Membres

Linda Parisien
Canada Health Infoway
Déconnecté(e)
Personne-ressource
Taylor Rubens-Augustson
CANImmunize Inc.
Déconnecté(e)
Admin
Cameron Bell
Ottawa Hospital Research Institute
Déconnecté(e)
Admin
Linda Monico
Canada Health Infoway
Déconnecté(e)
Admin
Karla Ortiz
CD-ED
Déconnecté(e)
Membre
Harmony Hill
Centre for Distance Education
Déconnecté(e)
Membre
Danielle Osborne
CDED
Déconnecté(e)
Membre
Sarrah D
CHIMA
Déconnecté(e)
Membre
Beverly Knight
n/a
Déconnecté(e)
Membre
Latifa Mnyusiwalla
Global Village
Déconnecté(e)
Membre
Lisa Hayes
Canada Health Infoway
Déconnecté(e)
Membre
Lorinda Broun
na
Déconnecté(e)
Membre
May Canning
Bc Centre For Disease Control
Déconnecté(e)
Membre
Shannon Butcher
Health Solutions LLC
Déconnecté(e)
Membre
Megan Adams
n/a
Déconnecté(e)
Membre

Voyez comment moderniser le processus d’ordonnances grâce à nos nouveaux modules d’enseignement en ligne.… https://t.co/tKwL3361HL

par Inforoute,

Logo d'InfoCentral

La santé numérique à votre service

 

Transformer les soins de santé au Canada grâce aux technologies de l'information sur la santé.



Login Register